India Rumored To Be Considering Price-Control Relief For Small Pharmas
This article was originally published in PharmAsia News
Executive Summary
About 5,000 small pharmaceutical companies could be freed of price controls under a plan being considered by India's government. The companies are ones located outside excise-free zones that have sales of $2.4 million or less. Authorities are believed to be considering such a move to relieve companies hit by the introduction of maximum retail prices at a time the prices of raw materials imported from China are rising. One senior government official denied, however, there was any move to exempt small pharmas from price controls. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.